# TROPION-Lung08 (NCT05215340)

> Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05215340
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Daiichi Sankyo
- Conditions: Metastatic Non Small Cell Lung Cancer
- Interventions: Datopotamab Deruxtecan; Pembrolizumab
- Enrollment: 740
- Primary outcome: Progression-free Survival Based on Blinded Independent Central Review in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab
- Primary outcome: Overall Survival (OS) in Participants With Non-Squamous Histology Who Were Administered Dato-DXd in Combination With Pembrolizumab Compared With Pembrolizumab

## Commentary we found

- YouTube: 15
- Podcasts: 6
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=tropion-lung08-nct05215340

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05215340", "email": "<work email>"}; the inbox owner confirms by the emailed link.